Wednesday, January 25, 2012

#DDP 2012: Scouting and Evaluation of Nanocarrier Technologies

Tomas Landh, Novo Nordisk

Why use nanoparticles?  What can they do?
  • -Overcome solubility
  • -Stability issues
  • -Limitations on route of administration
  • -Biocompartementalization
  • -Side effects of generalization drug administration

The size offers tremendous opportunities in chemistry.  It is critical to realize how enormously small these nanoparticles are.  You can build nanoparticle by aggregating them into macroparticles. 

What is forgotten when it comes to nano-particles?  Among other things, often the shape, specifically the forms of the particle and topology.  Topology, to this point, is a field that is largely unexplored.   Some examples of nanocarriers are micelles, vesicles, nanocapules, nanosphere, and dendrimers.   They are all spherical in shape.  When looking to dive deeper in the field, Landh suggests meeting and conversing with the universities known for that study.   On place to do this is through science forums.  Surprisingly, China is one of the countries most interested in nanoparticles and on the forefront of the technology. 

What is one of the biggest challenges for manufactures of the nanoparticles?  Human resources.  Often times, the best minds choose to go into other fields such as electornics.  If you build your particles from bottom up by self-assembly, you’ll do very little harm to your API. 

Mahesh Chaubal, Baxter Healthcare
Nanotechnology’s definition has been debated for a while.  The usual definition of a nano particle is any that are <1 micron.  Interestingly, for the most part, Pharma’s products don’t fit in the nano definition.  The benefit of nanotechnology is the ability to target places that can otherwise not be reached.

No comments:

Post a Comment